EMEA-001888-PIP01-15

Key facts

Active substance
  • Live, attenuated, chimeric dengue virus, serotype 1
  • live, attenuated dengue virus, serotype 2
  • live, attenuated, chimeric dengue virus, serotype 3
  • live attenuated, chimeric dengue virus, serotype 4
Therapeutic area
Vaccines
Decision number
P/0180/2017
PIP number
EMEA-001888-PIP01-15
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Prevention of dengue fever
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Takeda Vaccines, Inc.

Tel. +1 6174 442147
E-mail: amy.atwood@takeda.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating